We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 91.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$8.68M 0.06%
4,589
-10,851
-70% -$22.4M
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$8.24M 0.05%
250,000
– –
HALO icon
53
Halozyme
HALO
$9.88B
$8.18M 0.05%
449,969
-833,960
-65% -$14.6M
MNTA
54
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$8.11M 0.05%
308,500
– –
VKTX icon
55
Viking Therapeutics
VKTX
$3.87B
$7.4M 0.05%
+425,000
New +$5.06M
FSTX
56
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$7.39M 0.05%
153,286
+60,000
+64% +$3.01M
AUTL
57
Autolus Therapeutics
AUTL
$381M
$7.22M 0.05%
235,294
– –
VYNE icon
58
VYNE Therapeutics
VYNE
$6.89M 0.05%
194
– –
SYRS
59
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.85M 0.05%
57,484
– –
GTHX
60
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.65M 0.04%
127,236
-42,256
-25% -$2.3M
IFRX icon
61
InflaRx
IFRX
$249M
$6.14M 0.04%
178,987
-79,837
-31% -$2.58M
ACHN
62
DELISTED
Achillion Pharmaceuticals
ACHN
$6.04M 0.04%
1,639,948
-303,672
-16% -$905K
ARWR icon
63
Arrowhead Research
ARWR
$12B
$5.89M 0.04%
+307,496
New +$5.05M
ASMB icon
64
Assembly Biosciences
ASMB
$494M
$5.52M 0.04%
12,382
– –
NTLA icon
65
Intellia Therapeutics
NTLA
$1.52B
$5.51M 0.04%
192,538
-354,384
-65% -$10.3M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$5.23M 0.03%
414,029
– –
GNMX
67
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.86M 0.03%
3,950,419
-104,723
-3% -$117K
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$4.8M 0.03%
83,900
-80,000
-49% -$3.93M
GLMD icon
69
Galmed Pharmaceuticals
GLMD
$4.42M
$4.4M 0.03%
1,801
-1,733
-49% -$4.06M
ALKS icon
70
Alkermes
ALKS
$8.15B
$4.25M 0.03%
100,251
– –
YMAB
71
DELISTED
Y-mAbs Therapeutics
YMAB
$3.98M 0.03%
+150,000
New +$3.81M
FOMX
72
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.94M 0.03%
688,075
-802,126
-54% -$4.59M
CRNX icon
73
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.76M 0.02%
+131,250
New +$3.9M
FTSV
74
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.73M 0.02%
250,000
– –
APLS
75
DELISTED
Apellis Pharmaceuticals
APLS
$3.49M 0.02%
196,078
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Baker Bros. Advisors held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Baker Bros. Advisors's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Baker Bros. Advisors fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Baker Bros. Advisors opened 12 new positions and closed 27 in Q3 2018.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.